Low-Density Lipoprotein Receptor (LDLR) Is Involved in Internalization of Lentiviral Particles Pseudotyped with SARS-CoV-2 Spike Protein in Ocular Cells.
ARPE-19
LDL receptor
LDLR
S-protein
SARS-CoV-2
low-density lipoprotein receptor
ocular cells
spike protein
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
24 Jul 2023
24 Jul 2023
Historique:
received:
19
05
2023
revised:
16
07
2023
accepted:
17
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Here, we present evidence that caveolae-mediated endocytosis using LDLR is the pathway for SARS-CoV-2 virus internalization in the ocular cell line ARPE-19. Firstly, we found that, while Angiotensin-converting enzyme 2 (ACE2) is expressed in these cells, blocking ACE2 by antibody treatment did not prevent infection by SARS-CoV-2 spike pseudovirions, nor did antibody blockade of extracellular vimentin and other cholesterol-rich lipid raft proteins. Next, we implicated the role of cholesterol homeostasis in infection by showing that incubating cells with different cyclodextrins and oxysterol 25-hydroxycholesterol (25-HC) inhibits pseudovirion infection of ARPE-19. However, the effect of 25-HC is likely not via cholesterol biosynthesis, as incubation with lovastatin did not appreciably affect infection. Additionally, is it not likely to be an agonistic effect of 25-HC on LXR receptors, as the LXR agonist GW3965 had no significant effect on infection of ARPE-19 cells at up to 5 μM GW3965. We probed the role of endocytic pathways but determined that clathrin-dependent and flotillin-dependent rafts were not involved. Furthermore, 20 µM chlorpromazine, an inhibitor of clathrin-mediated endocytosis (CME), also had little effect. In contrast, anti-dynamin I/II antibodies blocked the entry of SARS-CoV-2 spike pseudovirions, as did dynasore, a noncompetitive inhibitor of dynamin GTPase activity. Additionally, anti-caveolin-1 antibodies significantly blocked spike pseudotyped lentiviral infection of ARPE-19. However, nystatin, a classic inhibitor of caveolae-dependent endocytosis, did not affect infection while indomethacin inhibited only at 10 µM at the 48 h time point. Finally, we found that anti-LDLR antibodies block pseudovirion infection to a similar degree as anti-caveolin-1 and anti-dynamin I/II antibodies, while transfection with LDLR-specific siRNA led to a decrease in spike pseudotyped lentiviral infection, compared to scrambled control siRNAs. Thus, we conclude that SARS-CoV-2 spike pseudovirion infection in ARPE-19 cells is a dynamin-dependent process that is primarily mediated by LDLR.
Identifiants
pubmed: 37511618
pii: ijms241411860
doi: 10.3390/ijms241411860
pmc: PMC10380832
pii:
doi:
Substances chimiques
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Cholesterol
97C5T2UQ7J
Clathrin
0
Dynamin II
EC 3.6.5.5
GW 3965
0
Lipoproteins, LDL
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
LDLR protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NEI NIH HHS
ID : Intramural Research Program
Pays : United States
Références
Methods Mol Biol. 2014;1195:133-44
pubmed: 24504930
J Biol Chem. 2013 Dec 13;288(50):35812-23
pubmed: 24189069
Front Cell Dev Biol. 2021 Feb 04;8:618296
pubmed: 33614627
Elife. 2021 Apr 23;10:
pubmed: 33890572
Cell Res. 2008 Feb;18(2):290-301
pubmed: 18227861
J Lipid Res. 2013 Aug;54(8):2174-2184
pubmed: 23733886
FEBS J. 2020 Sep;287(17):3664-3671
pubmed: 32428379
Science. 1986 Apr 4;232(4746):34-47
pubmed: 3513311
Molecules. 2016 Dec 20;21(12):
pubmed: 27999408
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Cell Stem Cell. 2021 Jul 1;28(7):1205-1220.e7
pubmed: 34022129
Signal Transduct Target Ther. 2022 Mar 11;7(1):83
pubmed: 35277473
Science. 2020 Nov 13;370(6518):856-860
pubmed: 33082293
Mol Biol Cell. 1993 Dec;4(12):1251-66
pubmed: 8167408
Front Immunol. 2021 Dec 16;12:796855
pubmed: 34975904
Cell Res. 2021 Feb;31(2):126-140
pubmed: 33420426
Cell Commun Signal. 2015 Apr 10;13:24
pubmed: 25889964
Oncotarget. 2017 Oct 19;8(61):103985-103995
pubmed: 29262615
Science. 2020 Nov 13;370(6518):861-865
pubmed: 33082294
Int J Biol Sci. 2020 Mar 15;16(10):1724-1731
pubmed: 32226290
Immunity. 2013 Jan 24;38(1):106-18
pubmed: 23273843
J Biol Chem. 2021 Jan-Jun;296:100306
pubmed: 33476648
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Biomolecules. 2020 Aug 21;10(9):
pubmed: 32825713
Cell Res. 2020 Nov;30(11):1043-1045
pubmed: 32811977
J Leukoc Biol. 2010 Dec;88(6):1081-7
pubmed: 20699362
Br J Pharmacol. 2021 Aug;178(16):3220-3234
pubmed: 32698250
Mol Vis. 2017 Mar 05;23:60-89
pubmed: 28356702
Nat Metab. 2020 Dec;2(12):1391-1400
pubmed: 33244168
Antivir Chem Chemother. 1998 Nov;9(6):491-6
pubmed: 9865387
Mol Biol Evol. 2005 May;22(5):1208-22
pubmed: 15703242
Exp Eye Res. 1996 Feb;62(2):155-69
pubmed: 8698076
Int J Mol Sci. 2021 Jun 17;22(12):
pubmed: 34204305
Lipids Health Dis. 2016 Jul 12;15(1):115
pubmed: 27405337
Front Med (Lausanne). 2021 Jan 05;7:620412
pubmed: 33469546
J Biol Chem. 1996 Jul 5;271(27):16026-34
pubmed: 8663188
J Lipid Res. 2014 Aug;55(8):1609-21
pubmed: 24664998
Viruses. 2020 Jul 06;12(7):
pubmed: 32640529
Lancet Infect Dis. 2023 Jun;23(6):655-656
pubmed: 37148902
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):
pubmed: 35078919
Chem Biol. 2010 Dec 22;17(12):1344-55
pubmed: 21168770
Virol J. 2021 Feb 27;18(1):46
pubmed: 33639976
Cells. 2021 Jun 07;10(6):
pubmed: 34200372
PLoS Genet. 2012;8(7):e1002764
pubmed: 22807683
Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2541-6
pubmed: 22936343
Nat Rev Immunol. 2020 Oct;20(10):592
pubmed: 32826975
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
PLoS One. 2020 Oct 15;15(10):e0240659
pubmed: 33057430
Traffic. 2015 Jun;16(6):635-54
pubmed: 25693808
Curr Opin Pharmacol. 2020 Aug;53:18-26
pubmed: 32361182
Cells. 2021 Jul 17;10(7):
pubmed: 34359983
Sci Transl Med. 2022 Dec 7;14(674):eabm9151
pubmed: 36137009
Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4239-44
pubmed: 22371602
Front Microbiol. 2020 Aug 11;11:1821
pubmed: 32849425
Obesity (Silver Spring). 2020 Dec;28(12):2357-2367
pubmed: 33043593
Cell. 2021 Apr 15;184(8):2212-2228.e12
pubmed: 33713620
J Virol. 2020 Jul 30;94(16):
pubmed: 32493827
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Eur J Biochem. 1989 Dec 8;186(1-2):17-22
pubmed: 2598927
Redox Biol. 2018 Oct;19:318-330
pubmed: 30212801
PLoS One. 2018 Jul 2;13(7):e0199012
pubmed: 29965997
Mol Cell Biochem. 2022 Mar;477(3):849-864
pubmed: 35066705
Nat Rev Genet. 2007 Nov;8(11):857-68
pubmed: 17943193
Nat Rev Immunol. 2022 Mar;22(3):144
pubmed: 35082449
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Curr Biol. 2000 Nov 16;10(22):R823-5
pubmed: 11102822